Drug Development
Bayer and NextRNA Therapeutics Collaborate on $547 Million Deal to Develop Innovative Cancer Therapies Targeting Long Non-Coding RNAs
Bayer, NextRNA Therapeutics, lncRNA, small molecules, cancer, oncology, partnership, drug development
Rafael Holdings and Cyclo Therapeutics Merge to Accelerate Development of Niemann-Pick Disease Type C1 Treatment
Rafael Holdings, Cyclo Therapeutics, merger, Niemann-Pick Disease Type C1, Trappsol Cyclo, clinical trial, pharmaceutical development
Metagenomi Halts ALS Research Following Biogen and Ionis Setbacks
Metagenomi, ALS program, Biogen, Ionis, pharmaceutical industry, drug development, layoffs, market challenges
23andMe Shifts Focus to GLP-1 Telehealth Offering, Cuts Internal Drug Development Team
23andMe, GLP-1, telehealth, weight loss, drug development, layoffs
Exelixis Abandons Tissue Factor-Targeting ADC Due to Competition from Tivdak
Exelixis, tissue factor-targeting ADC, Tivdak, biotech, pharmaceuticals, drug development
Roche Accelerates Obesity Drug Development and Explores M&A Opportunities
Roche, obesity drugs, M&A, pharmaceuticals, drug development
Pinetree Therapeutics Secures $17M in Funding to Advance Targeted Protein Degraders
Pinetree Therapeutics, targeted protein degraders, TPD, Series A funding, pharmaceutical development
Ventyx Abandons TYK2 Inhibitor Development Following Phase II Failure in Crohn’s Disease
Ventyx Biosciences, TYK2 inhibitor, VTX958, Crohn’s disease, Phase II trial, drug development failure
Ventyx Discontinues TYK2 Inhibitor Programme Following Second Mid-Stage Setback
Ventyx Biosciences, TYK2 inhibitor, VTX958, Phase 2 failure, psoriasis, psoriatic arthritis, Crohn’s disease, inflammatory diseases, drug development.
EvolutionaryScale Secures $142M for AI-Driven Drug Discovery
EvolutionaryScale, AI-driven drug discovery, $142M investment, drug development, pharmaceuticals